interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Patisiran Sodium

Generic competition · all medicines · read 12 November 2026

Is there a generic of Patisiran Sodium, and who makes it?

Patisiran Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Patisiran Sodium1 dosage-form group in the Orange Book
0generic makers listed
  1. Patisiran Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Onpattro. No generic is listed as marketed.

2015202020252030203501brand 2018data datePatent 8642076 listed to expire 3 October 2027Patent 8822668 listed to expire 15 April 2029Patent 9364435 listed to expire 15 April 2029Patent 11141378 listed to expire 15 April 2029Patent 8492359 listed to expire 15 April 2029Patent 8058069 listed to expire 15 April 2029Patent 9234196 listed to expire 20 October 2029Patent 8741866 listed to expire 20 October 2029Patent 10240152 listed to expire 20 October 2029Patent 8802644 listed to expire 21 October 2030Patent 8158601 listed to expire 10 November 2030Patent 8168775 listed to expire 10 August 2032Patent 11079379 listed to expire 27 August 2035
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 3 October 2027Patent 8642076 drug product
  • 15 April 2029Patent 8822668 drug product
  • 15 April 2029Patent 9364435 drug product
  • 15 April 2029Patent 11141378 drug product
  • 15 April 2029Patent 8492359 drug product
  • 15 April 2029Patent 8058069 drug product
  • 20 October 2029Patent 9234196 drug product
  • 20 October 2029Patent 8741866

5 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.